Safety and Pharmacokinetics of Clindamycin in Pediatric Subjects With BMI ≥ 85th Percentile

Phillip Brian Smith22 enrolled

Overview

The purpose of this study is to better understand how clindamycin works in children who fall in the 85th percentile or higher for body mass index (BMI - a ratio of weight to height). The results of the study will help better understand if children in higher BMI ranges process the medication differently and whether dosing should be adjusted in these children.

This is a prospective, open-label pharmacokinetic and safety study of multiple doses of IV and oral clindamycin in overweight and obese children ages 2 to 17 years of age. The total study duration is expected to be approximately 24 months; each subject will participate in the study for up to 18 days (screening day; treatment days 1-14 \[may be as short as 2 days\] followed by an observation period of 3 days post discontinuation of clindamycin therapy or after day 17 (on day 18) of therapy in those who are treated with more than 14 days of clindamycin).

Study Type

INTERVENTIONAL

Allocation

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Bacterial Infections Obesity

Interventions

ClindamycinDRUG

Schedule includes 30-40 mg/kg/day dosed every 6 or every 8 hours with a maximum daily dose of 2.7 grams/day. Dosing greater than 2.7g/day will be allowed for children receiving clindamycin as part of clinical care.

Eligibility

Sex: ALLMin age: 2 YearsMax age: 17 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 2 years - \< 18 years of age at the time of first dose of study drug * Suspected or confirmed infection OR receiving IV clindamycin per routine care * Negative serum pregnancy test (if female and has reached menarche) within 24 hours of first dose of study drug and agreement to practice appropriate contraceptive measures, including abstinence, from the time of the initial pregnancy test through the last dose of study drug * BMI ≥ 85th percentile for age and sex, based on Centers for Disease Control (CDC) recommendations * Signed informed consent/Health Insurance Portability and Accountability Act (HIPAA) documents by the parent/legal guardian and assent (if applicable) Exclusion Criteria: * The following apply only to those who are NOT already receiving clindamycin per routine care: 1. History of hypersensitivity or allergic reaction to clindamycin or lincomycin 2. History of C. difficile colitis with previous administration of clindamycin 3. Aspartate aminotransferase (AST) \> 120 units/L 4. Alanine aminotransferase (ALT) \> 210 units/L 5. Total bilirubin \> 3 mg/dL 6. Serum creatinine \> 2 mg/dL 7. Receiving a neuromuscular blocker as part of their therapy * Previous participation in the study * Subject is on prohibited medication or herbal product (see Appendix II) * Subject is receiving extracorporeal life support (ECLS) * Subject is post-cardiac bypass (within 24 hours) * Subject on inotropes/pressors * Any other condition or chronic illness that, in the opinion of the principal investigator, makes participation unadvised or unsafe

Locations (4)

Ann and Robert H. Lurie Children's Hospital of Chicago

Chicago, Illinois, United States

Children's Mercy Hospital

Kansas City, Kansas, United States

University of Louisville

Louisville, Kentucky, United States

Akron Children's Hospital

Akron, Ohio, United States

Outcomes

Primary Outcomes

Pharmacokinetics (PK) - Clearance (Cl) in Participants Who Received Multiple Doses of Intravenous (IV) Clindamycin.

In order to understand the impact of obesity on clindamycin PK, PK data were combined to build a PK model from 3 studies that included both obese and non-obese children: 1) PTN\_Clinda Obese study (clinicaltrials.gov/ct.gov identifier NCT01744730) n = 21; 2) PTN\_POPS study (ct.gov identifier NCT01431326) n = 178; and 3) Staph Trio study (ct.gov identifier NCT01728363) n = 21. The data from the Staph-Trio study were only included for PK modeling and not intended to be compared in the analysis. PK sampling schedule for PTN\_Clinda Obese was: Pre-dose 0 (within 15 minutes prior to IV clindamycin dose), 0.5 (± 5 minutes) after dose was administered, 1-1.5 hours (hrs) after dose, 3-4 hrs after, 5-6 hrs after, and pre-next dose. Samples were collected on multiple days and averaged to arrive at a single value. Comparison of empirical Bayesian Estimates (EBE) for clearance by age cohort are presented below. Sampling schedule details for PTN\_POPS and Staph Trio were comparable.

Time frame: After first study dose of IV Clindamycin through Day 14 (minimum of 3 samples; maximum of 6).

Pharmacokinetics (PK) - Clearance (Cl) in Participants Who Received Multiple Doses of Intravenous (IV) Clindamycin.

In order to understand the impact of obesity on clindamycin PK, PK data were combined to build a PK model from 3 studies that included both obese and non-obese children: 1) PTN\_Clinda Obese study (clinicaltrials.gov/ct.gov identifier NCT01744730) n = 21; 2) PTN\_POPS study (ct.gov identifier NCT01431326) n = 178; and 3) Staph Trio study (ct.gov identifier NCT01728363) n = 21. The data from the Staph-Trio study were only included for PK modeling and not intended to be compared in the analysis. PK sampling schedule for PTN\_Clinda Obese was: Pre-dose 0 (within 15 minutes prior to IV clindamycin dose), 0.5 (± 5 minutes) after dose was administered, 1-1.5 hours (hrs) after dose, 3-4 hrs after, 5-6 hrs after, and pre-next dose. Samples were collected on multiple days and averaged to arrive at a single value. Comparison of EBE for clearance by age cohort normalized to 1 kg of body weight are presented below. Sampling schedule details for PTN\_POPS and Staph Trio were comparable.

Time frame: After first study dose of IV Clindamycin through Day 14 (minimum of 3 samples; maximum of 6 samples).

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.